January 26, 2021
The decentralized research organization Care Access Research has teamed up with AstraZeneca to support the Phase III clinical trial for AZD7442, AstraZeneca’s long-acting monoclonal antibody combination for the potential prevention of COVID-19.
Using Care Access’s Mobile Sites On Demand, the two will develop, deploy and manage clinical research sites across the country to assess the safety and...
Credit: Qure.ai / AstraZeneca
December 8, 2020
Global biopharmaceutical company, AstraZeneca has announced a partnership through its Emerging Markets Health Innovation Hubs programme, with India-based AI solution provider, Qure.ai.
The partnership aims to to integrate AI solutions for the early detection of lung cancer in patients across AstraZeneca’s Emerging Markets regions, covering Latin America, Asia and the Middle East & Africa.
October 6, 2020
US tech giant NVIDIA has announced plans to build the UK’s most powerful supercomputer, to help healthcare researchers.
The Cambridge-1 supercomputer is expected to come online by the end of the year and is intended for artificial intelligence (AI) research into medical challenges, including those presented by COVID-19.
Speaking at his GPU Technology Conference keynote, NVIDIA founder and CEO,...
August 21, 2020
Artificial intelligence-enabled in vitro diagnostics company Renalytix AI announced today a research partnership with AstraZeneca to develop and launch medical strategies for cardiovascular, renal and metabolic diseases.
The first stage of the collaboration will use KidneyIntelX, an AI-enabled in vitro diagnostic platform that gathers patient data from electronic medical records to generate a...
August 4, 2020
Cardio-focused digital health company Eko has inked a deal with AstraZeneca in order for the two to work together to develop digital health-screening tools.
According to the companies, the pharm giant will be looking to employ Eko’s AI-enabled algorithms in developing early detection tools, as well as to use the tech in clinical trials.
WHY IT MATTERS
Heart disease accounts for roughly one in...
May 26, 2020
Digital respiratory health company Propeller Health has received 510(k) clearance for a sensor and app intended for use with AstraZeneca's Symbicort inhaler for asthma and COPD, the company announced today.
The tool – which, according to the agency, was submitted to the agency in September and greenlit in late March – was developed in a previously unannounced partnership with the Cambridge,...
March 30, 2020
MyHeritage, a genealogy and health DNA testing company, has teamed up with the Beijing Genomics Institute (BGI) to establish a COVID-19 testing lab in its home country of Israel, the Jerusalem Post reported on Saturday. The facility is aiming to open its doors by April 9 with a 10,000-tests-per-day capacity, and hopes to scale up to 20,000 per day shortly after.
“BGI will ship to Israel in the...
Credit: Piotr Swat/ Shutterstock.com
November 28, 2019
Anglo-Swedish drugmaker AstraZeneca has announced this week that it is launching an initiative that will see the company invest in Israel’s growing digital health space.
Called BeyondBio, the scheme follows a memorandum of understanding for investment in Israel signed earlier this year by AstraZeneca and the Israel Innovation Authority.
According to a press statement, the first...
March 20, 2019
Belfast-based data analytics company Diaceutics announced yesterday that it will seek listing on London’s junior stock exchange, the Alternative Investment Market (AIM).
The firm, which serves the global pharmaceutical industry, plans to float on Thursday with an expected market capitalisation of around £53m ($70m).
Diaceutics said in a press release that it has already raised £17m ($22.5m)...
January 24, 2018
New Zealand-based smart inhaler company Adherium, which up until now has distributed its products via pharma sales channels in Europe and Australia, plans to expand into the United States in the first half of 2018 with a direct-to-consumer (and direct-to-payer) strategy.
“We’ve had a great relationship over the last couple of years with AstraZeneca, we’ve launched in a couple dozen countries now...